No Data
No Data
BofA Securities Maintains BioXcel Therapeutics(BTAI.US) With Sell Rating, Cuts Target Price to $1
BioXcel Therapeutics Advances Clinical Trials and Reduces Losses
BioXcel Therapeutics | 10-K: FY2024 Annual Report
BioXcel Therapeutics Price Target Lowered to $1 From $4 at BofA
Bank of America Securities Keeps Their Sell Rating on Bioxcel Therapeutics (BTAI)
BioXcel Therapeutics | 8-K: BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024